Celcuity (NASDAQ:CELC) Director Richard Buller Sells 3,900 Shares

Celcuity, Inc. (NASDAQ:CELC) Director Richard Buller sold 3,900 shares of the stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $96.73, for a total value of $377,247.00. Following the sale, the director directly owned 7,260 shares in the company, valued at $702,259.80. This trade represents a 34.95% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Celcuity Price Performance

CELC stock traded up $3.50 during mid-day trading on Friday, reaching $97.50. 1,291,865 shares of the company traded hands, compared to its average volume of 740,403. The company has a debt-to-equity ratio of 2.74, a current ratio of 12.26 and a quick ratio of 12.26. The company has a market capitalization of $4.51 billion, a P/E ratio of -26.57 and a beta of 0.72. Celcuity, Inc. has a 52-week low of $7.57 and a 52-week high of $101.03. The company has a fifty day moving average price of $64.32 and a 200-day moving average price of $39.05.

Celcuity (NASDAQ:CELC) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($0.92) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.05) by $0.13. As a group, analysts anticipate that Celcuity, Inc. will post -2.62 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have issued reports on CELC. Wolfe Research assumed coverage on shares of Celcuity in a research note on Tuesday. They issued an “outperform” rating and a $110.00 target price on the stock. HC Wainwright reaffirmed a “neutral” rating and issued a $94.00 price target (up previously from $77.00) on shares of Celcuity in a report on Monday. Craig Hallum lifted their price objective on Celcuity from $96.00 to $108.00 and gave the company a “buy” rating in a research note on Thursday, November 13th. Needham & Company LLC set a $95.00 target price on Celcuity in a research report on Monday, October 20th. Finally, Stifel Nicolaus upped their target price on Celcuity from $68.00 to $115.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $97.00.

Institutional Investors Weigh In On Celcuity

Several hedge funds have recently added to or reduced their stakes in the company. Corton Capital Inc. purchased a new position in shares of Celcuity during the 2nd quarter valued at about $175,000. Trexquant Investment LP boosted its stake in Celcuity by 131.3% in the first quarter. Trexquant Investment LP now owns 26,920 shares of the company’s stock worth $272,000 after buying an additional 15,280 shares in the last quarter. Baker BROS. Advisors LP grew its position in Celcuity by 59.0% during the first quarter. Baker BROS. Advisors LP now owns 4,257,735 shares of the company’s stock valued at $43,046,000 after acquiring an additional 1,579,182 shares during the last quarter. Rhumbline Advisers raised its stake in shares of Celcuity by 8.9% during the first quarter. Rhumbline Advisers now owns 42,194 shares of the company’s stock worth $427,000 after acquiring an additional 3,439 shares in the last quarter. Finally, Nuveen LLC purchased a new position in shares of Celcuity during the first quarter worth approximately $704,000. Institutional investors own 63.33% of the company’s stock.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.